Skip to Content

Generic Epiduo Forte Availability

See also: Generic Epiduo

Epiduo Forte is a brand name of adapalene/benzoyl peroxide topical, approved by the FDA in the following formulation(s):

EPIDUO FORTE (adapalene; benzoyl peroxide - gel;topical)

  • Manufacturer: GALDERMA LABS
    Approval date: July 15, 2015
    Strength(s): 0.3%;2.5% [RLD]

Has a generic version of Epiduo Forte been approved?

No. There is currently no therapeutically equivalent version of Epiduo Forte available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epiduo Forte. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Combinations of adapalene and benzoyl peroxide for treating acne lesions
    Patent 8,445,543
    Issued: May 21, 2013
    Assignee(s): Galderma Research & Development
    Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.
    Patent expiration dates:
    • July 12, 2027
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent 8,703,820
    Issued: April 22, 2014
    Assignee(s): Galderma Research & Development
    Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Patent expiration dates:
    • March 12, 2023
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent 8,729,127
    Issued: May 20, 2014
    Assignee(s): Galderma Research & Development
    Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Patent expiration dates:
    • March 12, 2023
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Combination/association of adapalene and benzoyl peroxide for treating acne lesions
    Patent 8,785,420
    Issued: July 22, 2014
    Assignee(s): Galderma Research & Development
    Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
    Patent expiration dates:
    • December 23, 2022
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris
    Patent 8,809,305
    Issued: August 19, 2014
    Assignee(s): Galderma Research & Development
    A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
    Patent expiration dates:
    • December 23, 2022
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
    Patent 8,936,800
    Issued: January 20, 2015
    Assignee(s): Galderma Research & Development
    Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
    Patent expiration dates:
    • December 23, 2022
      ✓ 
      Patent use: TREATMENT OF ACNE
      ✓ 
      Drug product
  • Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent 9,381,179
    Issued: July 5, 2016
    Assignee(s): GALDERMA RESEARCH & DEVELOPMENT
    Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Patent expiration dates:
    • March 12, 2023
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
    Patent 9,387,187
    Issued: July 12, 2016
    Assignee(s): GALDERMA RESEARCH & DEVELOPMENT
    Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Patent expiration dates:
    • March 12, 2023
      ✓ 
      Patent use: TREATMENT OF ACNE

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 15, 2018 - NEW PRODUCT

More about Epiduo Forte (adapalene / benzoyl peroxide topical)

Consumer resources

Related treatment guides

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide